Background: Embryonic stem cell expressed Ras (ERas) oncogene is associated with the tumorigenicity of embryonic stem cells. The aim of this study was to clarify the significance of ERas expression in clinical samples of gastric carcinomas.
Materials And Methods: Three hundred and few tissues from gastric cancer patients were analyzed by immunohistochemical techniques using an anti-ERas antibody. ERas mRNA expression in 77 gastric carcinomas was examined by reverse-transcription polymerase chain reaction.
Results: ERas expression was positive in 135 (44%) of 304 gastric carcinomas. ERas-positive expression had a significant relationship with invasion depth (p<0.01), histological type (p<0.01), clinical stage (p=0.013) and curability (p=0.001). Prognosis of ERas-negative patients was significantly (p=0.029) poorer than that of ERas-positive patients, while ERas was not an independent prognostic factor. Expression of ERas mRNA was found in 35 (45%) out of 77 gastric cancer tissues.
Conclusion: ERas oncogene is associated with the tumorigenic process of human gastric carcinomas.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Intraspecific diversity is critical to population-level risk assessments.
Sci Rep
October 2024
Department of Integrative Biology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Environmental risk assessment (ERA) is critical for protecting life by predicting population responses to contaminants. However, routine toxicity testing often examines only one genotype from surrogate species, potentially leading to inaccurate risk assessments, as natural populations typically consist of genetically diverse individuals. To evaluate the importance of intraspecific variation in translating toxicity testing to natural populations, we quantified the magnitude of phenotypic variation between 20 Daphnia magna clones exposed to two levels of microcystins, a cosmopolitan cyanobacterial toxin.
View Article and Find Full Text PDFImproved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors.
Anticancer Res
May 2024
Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Background/aim: The treatment for chronic lymphocytic leukemia (CLL) has changed dramatically over the last two decades. The current study aimed to investigate the impact on overall survival (OS) and time to next treatment (TTT) among CLL patients from 1998 to 2022.
Patients And Methods: The cohort was based on data obtained from electronic medical records of Maccabi, the second largest healthcare organization in Israel.
Improved long-term outcomes after innovative preoperative evaluation and conception of precise surgery for gallbladder cancer.
Cancer Med
September 2023
Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: Three-dimensional visualization preoperative evaluation (3D-VPE) and enhanced recovery after surgery (ERAS) have been suggested to improve outcomes of cancer surgery in patients, yet little is known regarding their clinical benefit in patients with gallbladder cancer (GBC). We hypothesized that the combination of 3D-VPE and ERAS would improve the outcome of patients undergoing surgery for GBC.
Objective: This study aimed to determine if 3D-VPE and ERAS can improve the outcomes and overall survival in patients with GBC, establishing a novel patient management strategy for GBC.
The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024.
Toxicol Appl Pharmacol
September 2023
Erasca Therapeutics, USA.
Two potent and selective KRAS inhibitors, ERAS-4693 and ERAS-5024, were generated as possible clinical candidates to treat patients harboring G12D mutations in solid tumors. Both molecules exhibited strong anti-tumor activity in the KRAS mutant PDAC xenograft mouse models while ERAS-5024 also showed tumor growth inhibition when administered on an intermittent dosing regimen. Acute dose-limiting toxicity consistent with an allergic reaction was observed for both molecules shortly after administration at doses just above those which demonstrated anti-tumor activity, indicative of a narrow therapeutic index.
View Article and Find Full Text PDFSecond Primary Cancers in People With HIV/AIDS: A National Data Linkage Study of Incidence and Risk Factors.
J Acquir Immune Defic Syndr
May 2023
The Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia.
Background: Evidence regarding the characteristics of second primary cancer (SPC) in people living with HIV (PLWHIV) is limited.
Setting: We performed a national population-based data linkage study to determine the incidence and risk factors of SPC in PLWHIV in Australia between 1982 and 2012.
Methods: We conducted a probabilistic data linkage study to compare the incidence of SPC over time, defined using HIV treatment eras, for SPCs related to oncogenic viral infection in comparison with non-infection-related SPCs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!